Global Breast Cancer Diagnostics Market
Global Breast Cancer Diagnostics Market

Breast Cancer Diagnostics Comprehensive Study by Type (Ionizing Breast Imaging Technologies (Analog Mammography, Full-Field Digital Mammography (FFDM), 3D Breast Tomosynthesis, Positron Emission Tomography/ Computed Tomography (PET/CT), Molecular Breast Imaging/ Breast Specific Gamma Imaging (MBI/BSMI), Positron Emission Mammography, and Others), Non-ionizing Imaging Technologies (Breast MRI (Magnetic Resonance Imaging), Breast Ultrasound, Optical Imaging, Automated Whole Breast Ultrasound (AWBU), and Breast Thermography)), Application (Diagnostic Clinical Laboratories, Hospitals Associated Laboratories, Ambulatory Surgical Centres, Cancer Research Centres), Test (BRCA, ER & PR, CEA, KRAS Mutation, HER 2, PSA, CA Test, EGFR Mutation Test, Immunohistochemistry, Biopsy, Blood Tests, Imaging, Genomic Tests, Others) Players and Region - Global Market Outlook to 2026

Breast Cancer Diagnostics Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

May 2021 Edition 248 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Breast Cancer Diagnostics Market Overview:
The breast cancer diagnostics market is predicted to expand in the future as the prevalence of cancer rises and the government attempts to improve screening and diagnosis increase. The market for breast cancer diagnostics is predicted to grow as the prevalence of breast cancer rises. In the forecast term, the expanding elderly population, together with technological advancements, would provide numerous chances for the breast cancer diagnostics market to develop.

Growth Drivers
  • Increasing Incidence Of Breast Cancer
  • Growth in the Number of Private Diagnostic Center

Market Trends
  • Technological Advancements in Diagnosis Procedure

Roadblocks
  • Adverse Effects Of Screening Procedures

Opportunities
  • Favorable Reimbursement Framework For Breast Cancer Diagnosis
  • Early Detection And Increase In Awareness About Breast Cancer

Challenges
  • Lack of Skilled and Experienced Personnel
  • Rising Need of High Capital Investment


Competitive Landscape:
The global Breast Cancer Diagnostics market is fragmented due to the presence of regional and global manufacturers. The level of competition among the companies in the Breast Cancer Diagnostics market is intense and manufacturers focus on developing new technologies. In the coming years, manufacturers will also develop new partnerships to spread their product reach to more customers globally.
Some of the key players profiled in the report are Hologic Inc. (United States), Genomic Health (United States), BD (United States), Danaher (United States), Koninklijke Philips N.V. (Netherlands), QIAGEN (Germany), Thermo Fisher Scientific Inc. (United States), Myriad Genetics (United States), Argon Medical Devices, Inc. (United States) and F. Hoffmann-La Roche Ltd. (Switzerland). Analyst at AMA Research see United States Players to retain maximum share of Global Breast Cancer Diagnostics market by 2026. Considering Market by Test, the sub-segment i.e. BRCA will boost the Breast Cancer Diagnostics market.

Latest Market Insights:
In Jan 2021, Hologic Inc. acquired Biotheranostics and SOMATEX Medical Technologies GmbH. The acquisition of these companies has helped the company to expand its breast health product portfolio and strengthen its position in the market for breast cancer diagnostics.

In Sept 2020, Thermo Fisher Scientific, Inc. entered into an agreement with AstraZeneca and the University of Nebraska Medical Center for the development of innovative clinical biomarkers.

What Can be Explored with the Breast Cancer Diagnostics Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Breast Cancer Diagnostics Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Breast Cancer Diagnostics
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Breast Cancer Diagnostics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Breast Cancer Diagnostics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Breast Cancer Diagnostics Equipment Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Ionizing Breast Imaging Technologies (Analog Mammography, Full-Field Digital Mammography (FFDM), 3D Breast Tomosynthesis, Positron Emission Tomography/ Computed Tomography (PET/CT), Molecular Breast Imaging/ Breast Specific Gamma Imaging (MBI/BSMI), Positron Emission Mammography, and Others)
  • Non-ionizing Imaging Technologies (Breast MRI (Magnetic Resonance Imaging), Breast Ultrasound, Optical Imaging, Automated Whole Breast Ultrasound (AWBU), and Breast Thermography)
By Application
  • Diagnostic Clinical Laboratories
  • Hospitals Associated Laboratories
  • Ambulatory Surgical Centres
  • Cancer Research Centres
By Test
  • BRCA
  • ER & PR
  • CEA
  • KRAS Mutation
  • HER 2
  • PSA
  • CA Test
  • EGFR Mutation Test
  • Immunohistochemistry
  • Biopsy
  • Blood Tests
  • Imaging
  • Genomic Tests
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence Of Breast Cancer
      • 3.2.2. Growth in the Number of Private Diagnostic Center
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled and Experienced Personnel
      • 3.3.2. Rising Need of High Capital Investment
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Diagnosis Procedure
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Breast Cancer Diagnostics, by Type, Application, Test and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Breast Cancer Diagnostics (Value)
      • 5.2.1. Global Breast Cancer Diagnostics by: Type (Value)
        • 5.2.1.1. Ionizing Breast Imaging Technologies (Analog Mammography, Full-Field Digital Mammography (FFDM), 3D Breast Tomosynthesis, Positron Emission Tomography/ Computed Tomography (PET/CT), Molecular Breast Imaging/ Breast Specific Gamma Imaging (MBI/BSMI), Positron Emission Mammography, and Others)
        • 5.2.1.2. Non-ionizing Imaging Technologies (Breast MRI (Magnetic Resonance Imaging), Breast Ultrasound, Optical Imaging, Automated Whole Breast Ultrasound (AWBU), and Breast Thermography)
      • 5.2.2. Global Breast Cancer Diagnostics by: Application (Value)
        • 5.2.2.1. Diagnostic Clinical Laboratories
        • 5.2.2.2. Hospitals Associated Laboratories
        • 5.2.2.3. Ambulatory Surgical Centres
        • 5.2.2.4. Cancer Research Centres
      • 5.2.3. Global Breast Cancer Diagnostics by: Test (Value)
        • 5.2.3.1. BRCA
        • 5.2.3.2. ER & PR
        • 5.2.3.3. CEA
        • 5.2.3.4. KRAS Mutation
        • 5.2.3.5. HER 2
        • 5.2.3.6. PSA
        • 5.2.3.7. CA Test
        • 5.2.3.8. EGFR Mutation Test
        • 5.2.3.9. Immunohistochemistry
        • 5.2.3.10. Biopsy
        • 5.2.3.11. Blood Tests
        • 5.2.3.12. Imaging
        • 5.2.3.13. Genomic Tests
        • 5.2.3.14. Others
      • 5.2.4. Global Breast Cancer Diagnostics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Breast Cancer Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Hologic Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Genomic Health (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BD (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Danaher (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Koninklijke Philips N.V. (Netherlands)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. QIAGEN (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Thermo Fisher Scientific Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Myriad Genetics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Argon Medical Devices, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Breast Cancer Diagnostics Sale, by Type, Application, Test and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Breast Cancer Diagnostics (Value)
      • 7.2.1. Global Breast Cancer Diagnostics by: Type (Value)
        • 7.2.1.1. Ionizing Breast Imaging Technologies (Analog Mammography, Full-Field Digital Mammography (FFDM), 3D Breast Tomosynthesis, Positron Emission Tomography/ Computed Tomography (PET/CT), Molecular Breast Imaging/ Breast Specific Gamma Imaging (MBI/BSMI), Positron Emission Mammography, and Others)
        • 7.2.1.2. Non-ionizing Imaging Technologies (Breast MRI (Magnetic Resonance Imaging), Breast Ultrasound, Optical Imaging, Automated Whole Breast Ultrasound (AWBU), and Breast Thermography)
      • 7.2.2. Global Breast Cancer Diagnostics by: Application (Value)
        • 7.2.2.1. Diagnostic Clinical Laboratories
        • 7.2.2.2. Hospitals Associated Laboratories
        • 7.2.2.3. Ambulatory Surgical Centres
        • 7.2.2.4. Cancer Research Centres
      • 7.2.3. Global Breast Cancer Diagnostics by: Test (Value)
        • 7.2.3.1. BRCA
        • 7.2.3.2. ER & PR
        • 7.2.3.3. CEA
        • 7.2.3.4. KRAS Mutation
        • 7.2.3.5. HER 2
        • 7.2.3.6. PSA
        • 7.2.3.7. CA Test
        • 7.2.3.8. EGFR Mutation Test
        • 7.2.3.9. Immunohistochemistry
        • 7.2.3.10. Biopsy
        • 7.2.3.11. Blood Tests
        • 7.2.3.12. Imaging
        • 7.2.3.13. Genomic Tests
        • 7.2.3.14. Others
      • 7.2.4. Global Breast Cancer Diagnostics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Breast Cancer Diagnostics: by Type(USD Million)
  • Table 2. Breast Cancer Diagnostics Ionizing Breast Imaging Technologies (Analog Mammography, Full-Field Digital Mammography (FFDM), 3D Breast Tomosynthesis, Positron Emission Tomography/ Computed Tomography (PET/CT), Molecular Breast Imaging/ Breast Specific Gamma Imaging (MBI/BSMI), Positron Emission Mammography, and Others) , by Region USD Million (2015-2020)
  • Table 3. Breast Cancer Diagnostics Non-ionizing Imaging Technologies (Breast MRI (Magnetic Resonance Imaging), Breast Ultrasound, Optical Imaging, Automated Whole Breast Ultrasound (AWBU), and Breast Thermography) , by Region USD Million (2015-2020)
  • Table 4. Breast Cancer Diagnostics: by Application(USD Million)
  • Table 5. Breast Cancer Diagnostics Diagnostic Clinical Laboratories , by Region USD Million (2015-2020)
  • Table 6. Breast Cancer Diagnostics Hospitals Associated Laboratories , by Region USD Million (2015-2020)
  • Table 7. Breast Cancer Diagnostics Ambulatory Surgical Centres , by Region USD Million (2015-2020)
  • Table 8. Breast Cancer Diagnostics Cancer Research Centres , by Region USD Million (2015-2020)
  • Table 9. Breast Cancer Diagnostics: by Test(USD Million)
  • Table 10. Breast Cancer Diagnostics BRCA , by Region USD Million (2015-2020)
  • Table 11. Breast Cancer Diagnostics ER & PR , by Region USD Million (2015-2020)
  • Table 12. Breast Cancer Diagnostics CEA , by Region USD Million (2015-2020)
  • Table 13. Breast Cancer Diagnostics KRAS Mutation , by Region USD Million (2015-2020)
  • Table 14. Breast Cancer Diagnostics HER 2 , by Region USD Million (2015-2020)
  • Table 15. Breast Cancer Diagnostics PSA , by Region USD Million (2015-2020)
  • Table 16. Breast Cancer Diagnostics CA Test , by Region USD Million (2015-2020)
  • Table 17. Breast Cancer Diagnostics EGFR Mutation Test , by Region USD Million (2015-2020)
  • Table 18. Breast Cancer Diagnostics Immunohistochemistry , by Region USD Million (2015-2020)
  • Table 19. Breast Cancer Diagnostics Biopsy , by Region USD Million (2015-2020)
  • Table 20. Breast Cancer Diagnostics Blood Tests , by Region USD Million (2015-2020)
  • Table 21. Breast Cancer Diagnostics Imaging , by Region USD Million (2015-2020)
  • Table 22. Breast Cancer Diagnostics Genomic Tests , by Region USD Million (2015-2020)
  • Table 23. Breast Cancer Diagnostics Others , by Region USD Million (2015-2020)
  • Table 24. South America Breast Cancer Diagnostics, by Country USD Million (2015-2020)
  • Table 25. South America Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 26. South America Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 27. South America Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 28. Brazil Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 29. Brazil Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 30. Brazil Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 31. Argentina Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 32. Argentina Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 33. Argentina Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 34. Rest of South America Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 35. Rest of South America Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 36. Rest of South America Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 37. Asia Pacific Breast Cancer Diagnostics, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 39. Asia Pacific Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 40. Asia Pacific Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 41. China Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 42. China Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 43. China Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 44. Japan Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 45. Japan Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 46. Japan Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 47. India Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 48. India Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 49. India Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 50. South Korea Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 51. South Korea Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 52. South Korea Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 53. Taiwan Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 54. Taiwan Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 55. Taiwan Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 56. Australia Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 57. Australia Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 58. Australia Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 62. Europe Breast Cancer Diagnostics, by Country USD Million (2015-2020)
  • Table 63. Europe Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 64. Europe Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 65. Europe Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 66. Germany Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 67. Germany Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 68. Germany Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 69. France Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 70. France Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 71. France Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 72. Italy Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 73. Italy Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 74. Italy Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 75. United Kingdom Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 76. United Kingdom Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 77. United Kingdom Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 78. Netherlands Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 79. Netherlands Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 80. Netherlands Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 81. Rest of Europe Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 82. Rest of Europe Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 83. Rest of Europe Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 84. MEA Breast Cancer Diagnostics, by Country USD Million (2015-2020)
  • Table 85. MEA Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 86. MEA Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 87. MEA Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 88. Middle East Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 89. Middle East Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 90. Middle East Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 91. Africa Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 92. Africa Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 93. Africa Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 94. North America Breast Cancer Diagnostics, by Country USD Million (2015-2020)
  • Table 95. North America Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 96. North America Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 97. North America Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 98. United States Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 99. United States Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 100. United States Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 101. Canada Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 102. Canada Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 103. Canada Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 104. Mexico Breast Cancer Diagnostics, by Type USD Million (2015-2020)
  • Table 105. Mexico Breast Cancer Diagnostics, by Application USD Million (2015-2020)
  • Table 106. Mexico Breast Cancer Diagnostics, by Test USD Million (2015-2020)
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Breast Cancer Diagnostics: by Type(USD Million)
  • Table 118. Breast Cancer Diagnostics Ionizing Breast Imaging Technologies (Analog Mammography, Full-Field Digital Mammography (FFDM), 3D Breast Tomosynthesis, Positron Emission Tomography/ Computed Tomography (PET/CT), Molecular Breast Imaging/ Breast Specific Gamma Imaging (MBI/BSMI), Positron Emission Mammography, and Others) , by Region USD Million (2021-2026)
  • Table 119. Breast Cancer Diagnostics Non-ionizing Imaging Technologies (Breast MRI (Magnetic Resonance Imaging), Breast Ultrasound, Optical Imaging, Automated Whole Breast Ultrasound (AWBU), and Breast Thermography) , by Region USD Million (2021-2026)
  • Table 120. Breast Cancer Diagnostics: by Application(USD Million)
  • Table 121. Breast Cancer Diagnostics Diagnostic Clinical Laboratories , by Region USD Million (2021-2026)
  • Table 122. Breast Cancer Diagnostics Hospitals Associated Laboratories , by Region USD Million (2021-2026)
  • Table 123. Breast Cancer Diagnostics Ambulatory Surgical Centres , by Region USD Million (2021-2026)
  • Table 124. Breast Cancer Diagnostics Cancer Research Centres , by Region USD Million (2021-2026)
  • Table 125. Breast Cancer Diagnostics: by Test(USD Million)
  • Table 126. Breast Cancer Diagnostics BRCA , by Region USD Million (2021-2026)
  • Table 127. Breast Cancer Diagnostics ER & PR , by Region USD Million (2021-2026)
  • Table 128. Breast Cancer Diagnostics CEA , by Region USD Million (2021-2026)
  • Table 129. Breast Cancer Diagnostics KRAS Mutation , by Region USD Million (2021-2026)
  • Table 130. Breast Cancer Diagnostics HER 2 , by Region USD Million (2021-2026)
  • Table 131. Breast Cancer Diagnostics PSA , by Region USD Million (2021-2026)
  • Table 132. Breast Cancer Diagnostics CA Test , by Region USD Million (2021-2026)
  • Table 133. Breast Cancer Diagnostics EGFR Mutation Test , by Region USD Million (2021-2026)
  • Table 134. Breast Cancer Diagnostics Immunohistochemistry , by Region USD Million (2021-2026)
  • Table 135. Breast Cancer Diagnostics Biopsy , by Region USD Million (2021-2026)
  • Table 136. Breast Cancer Diagnostics Blood Tests , by Region USD Million (2021-2026)
  • Table 137. Breast Cancer Diagnostics Imaging , by Region USD Million (2021-2026)
  • Table 138. Breast Cancer Diagnostics Genomic Tests , by Region USD Million (2021-2026)
  • Table 139. Breast Cancer Diagnostics Others , by Region USD Million (2021-2026)
  • Table 140. South America Breast Cancer Diagnostics, by Country USD Million (2021-2026)
  • Table 141. South America Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 142. South America Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 143. South America Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 144. Brazil Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 145. Brazil Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 146. Brazil Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 147. Argentina Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 148. Argentina Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 149. Argentina Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 150. Rest of South America Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 151. Rest of South America Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 152. Rest of South America Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 153. Asia Pacific Breast Cancer Diagnostics, by Country USD Million (2021-2026)
  • Table 154. Asia Pacific Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 155. Asia Pacific Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 156. Asia Pacific Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 157. China Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 158. China Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 159. China Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 160. Japan Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 161. Japan Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 162. Japan Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 163. India Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 164. India Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 165. India Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 166. South Korea Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 167. South Korea Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 168. South Korea Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 169. Taiwan Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 170. Taiwan Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 171. Taiwan Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 172. Australia Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 173. Australia Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 174. Australia Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 175. Rest of Asia-Pacific Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 176. Rest of Asia-Pacific Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 177. Rest of Asia-Pacific Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 178. Europe Breast Cancer Diagnostics, by Country USD Million (2021-2026)
  • Table 179. Europe Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 180. Europe Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 181. Europe Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 182. Germany Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 183. Germany Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 184. Germany Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 185. France Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 186. France Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 187. France Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 188. Italy Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 189. Italy Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 190. Italy Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 191. United Kingdom Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 192. United Kingdom Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 193. United Kingdom Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 194. Netherlands Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 195. Netherlands Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 196. Netherlands Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 197. Rest of Europe Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 198. Rest of Europe Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 199. Rest of Europe Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 200. MEA Breast Cancer Diagnostics, by Country USD Million (2021-2026)
  • Table 201. MEA Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 202. MEA Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 203. MEA Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 204. Middle East Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 205. Middle East Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 206. Middle East Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 207. Africa Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 208. Africa Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 209. Africa Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 210. North America Breast Cancer Diagnostics, by Country USD Million (2021-2026)
  • Table 211. North America Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 212. North America Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 213. North America Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 214. United States Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 215. United States Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 216. United States Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 217. Canada Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 218. Canada Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 219. Canada Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 220. Mexico Breast Cancer Diagnostics, by Type USD Million (2021-2026)
  • Table 221. Mexico Breast Cancer Diagnostics, by Application USD Million (2021-2026)
  • Table 222. Mexico Breast Cancer Diagnostics, by Test USD Million (2021-2026)
  • Table 223. Research Programs/Design for This Report
  • Table 224. Key Data Information from Secondary Sources
  • Table 225. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Breast Cancer Diagnostics: by Type USD Million (2015-2020)
  • Figure 5. Global Breast Cancer Diagnostics: by Application USD Million (2015-2020)
  • Figure 6. Global Breast Cancer Diagnostics: by Test USD Million (2015-2020)
  • Figure 7. South America Breast Cancer Diagnostics Share (%), by Country
  • Figure 8. Asia Pacific Breast Cancer Diagnostics Share (%), by Country
  • Figure 9. Europe Breast Cancer Diagnostics Share (%), by Country
  • Figure 10. MEA Breast Cancer Diagnostics Share (%), by Country
  • Figure 11. North America Breast Cancer Diagnostics Share (%), by Country
  • Figure 12. Global Breast Cancer Diagnostics share by Players 2020 (%)
  • Figure 13. Global Breast Cancer Diagnostics share by Players (Top 3) 2020(%)
  • Figure 14. Global Breast Cancer Diagnostics share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Hologic Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Hologic Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Genomic Health (United States) Revenue, Net Income and Gross profit
  • Figure 19. Genomic Health (United States) Revenue: by Geography 2020
  • Figure 20. BD (United States) Revenue, Net Income and Gross profit
  • Figure 21. BD (United States) Revenue: by Geography 2020
  • Figure 22. Danaher (United States) Revenue, Net Income and Gross profit
  • Figure 23. Danaher (United States) Revenue: by Geography 2020
  • Figure 24. Koninklijke Philips N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 25. Koninklijke Philips N.V. (Netherlands) Revenue: by Geography 2020
  • Figure 26. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 27. QIAGEN (Germany) Revenue: by Geography 2020
  • Figure 28. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Myriad Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 31. Myriad Genetics (United States) Revenue: by Geography 2020
  • Figure 32. Argon Medical Devices, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Argon Medical Devices, Inc. (United States) Revenue: by Geography 2020
  • Figure 34. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 36. Global Breast Cancer Diagnostics: by Type USD Million (2021-2026)
  • Figure 37. Global Breast Cancer Diagnostics: by Application USD Million (2021-2026)
  • Figure 38. Global Breast Cancer Diagnostics: by Test USD Million (2021-2026)
  • Figure 39. South America Breast Cancer Diagnostics Share (%), by Country
  • Figure 40. Asia Pacific Breast Cancer Diagnostics Share (%), by Country
  • Figure 41. Europe Breast Cancer Diagnostics Share (%), by Country
  • Figure 42. MEA Breast Cancer Diagnostics Share (%), by Country
  • Figure 43. North America Breast Cancer Diagnostics Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Hologic Inc. (United States)
  • Genomic Health (United States)
  • BD (United States)
  • Danaher (United States)
  • Koninklijke Philips N.V. (Netherlands)
  • QIAGEN (Germany)
  • Thermo Fisher Scientific Inc. (United States)
  • Myriad Genetics (United States)
  • Argon Medical Devices, Inc. (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation